NervGen Pharma announced on February 12, 2026, that Bill Adams will retire as Chief Financial Officer effective March 15, 2026.134
The company has engaged a leading executive search firm to identify a successor, and Mr. Adams will continue in an advisory capacity post-retirement to ensure a smooth transition.12
Bill Adams served for six years, contributing to the company's growth from preclinical stages to Nasdaq listing and late-stage development of NVG-291 for spinal cord injury.1
CEO Adam Rogers praised Adams for his financial leadership and dedication.1
Market reaction has been muted, with stock at $4.12, focusing on clinical catalysts like Phase 1b/2a data for NVG-291 rather than the CFO change.2
Sources:
1. https://nervgen.com/nervgen-pharma-announces-retirement-of-chief-financial-officer-bill-adams/
2. https://www.ainvest.com/news/nervgen-cfo-change-impact-transition-clinical-catalysts-2602/
3. https://www.tipranks.com/news/company-announcements/nervgen-pharma-cfo-to-retire-as-company-advances-late-stage-sci-program